The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer (KDOG 0501-P2).
Katsuhiko Higuchi
No relevant relationships to disclose
Shouko Komori
No relevant relationships to disclose
Satoshi Tanabe
No relevant relationships to disclose
Chikatoshi Katada
No relevant relationships to disclose
Mizutomo Azuma
No relevant relationships to disclose
Hiromichi Ishiyama
No relevant relationships to disclose
Tohru Sasaki
No relevant relationships to disclose
Kenji Ishido
No relevant relationships to disclose
Natsuya Katada
No relevant relationships to disclose
Kazushige Hayakawa
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose